Literature DB >> 8958204

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.

C C Tseng1, T J Kieffer, L A Jarboe, T B Usdin, M M Wolfe.   

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide produced by K cells of the mammalian proximal small intestine and is a potent stimulant of insulin release in the presence of hyperglycemia. However, its relative physiological importance as a postprandial insulinotropic agent is unknown. Using LGIPR2 cells stably transfected with rat GIP receptor cDNA, GIP (1-42) stimulation of cyclic adenosine monophosphate (cAMP) production was inhibited in a concentration-dependent manner by GIP (7-30)-NH2. Competition binding assays using stably transfected L293 cells demonstrated an IC50 for GIP receptor binding of 7 nmol/liter for GIP (1-42) and 200 nmol/liter for GIP (7-30)-NH2, whereas glucagonlike peptide-1 (GLP-1) binding to its receptor on ++betaTC3 cells was minimally displaced by GIP (7-30)-NH2. In fasted anesthetized rats, GIP (1-42) stimulated insulin release in a concentration-dependent manner, an effect abolished by the concomitant intraperitoneal administration of GIP (7-30)-NH2 (100 nmol/ kg). In contrast, glucose-, GLP-1-, and arginine-stimulated insulin release were not affected by GIP (7-30)-NH2. In separate experiments, GIP (7-30)-NH2 (100 nmol/kg) reduced postprandial insulin release in conscious rats by 72%. It is concluded that GIP (7-30)-NH2 is a GIP-specific receptor antagonist and that GIP plays a dominant role in mediating postprandial insulin release.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958204      PMCID: PMC507699          DOI: 10.1172/JCI119060

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Simultaneous sampling of blood, bile, and urine in rats for pharmacokinetic studies.

Authors:  Z X Xu; S Melethil
Journal:  J Pharmacol Methods       Date:  1990-11

2.  Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets.

Authors:  E G Siegel; A Schulze; W E Schmidt; W Creutzfeldt
Journal:  Eur J Clin Invest       Date:  1992-03       Impact factor: 4.686

3.  Potential incretins.

Authors:  L T Shuster; V L Go; R A Rizza; P C O'Brien; F J Service
Journal:  Mayo Clin Proc       Date:  1988-08       Impact factor: 7.616

4.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

Authors:  J Dupre; S A Ross; D Watson; J C Brown
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

5.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Authors:  S Mojsov; G C Weir; J F Habener
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

6.  Gastrointestinal peptides and insulin secretion.

Authors:  R Ebert; W Creutzfeldt
Journal:  Diabetes Metab Rev       Date:  1987-01

7.  Effect of glucagon-like peptide-1 on insulin secretion.

Authors:  K Shima; M Hirota; C Ohboshi
Journal:  Regul Pept       Date:  1988-08

8.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

Authors:  M A Nauck; E Bartels; C Orskov; R Ebert; W Creutzfeldt
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

9.  Glucose-dependent insulinotropic polypeptide stimulated insulin release from a tumor-derived beta-cell line (beta TC3).

Authors:  T J Kieffer; C B Verchere; C D Fell; Z Huang; J C Brown; R A Pedersen
Journal:  Can J Physiol Pharmacol       Date:  1993-12       Impact factor: 2.273

10.  Circadian rhythm of gastric inhibitory polypeptide (GIP) in man.

Authors:  M Salera; P Giacomoni; L Pironi; C Ustra; M Capelli; A Giorgi; M Miglioli; L Barbara
Journal:  Metabolism       Date:  1983-01       Impact factor: 8.694

View more
  25 in total

1.  Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells.

Authors:  Daniel Prabakaran; Baogui Wang; Joseph D Feuerstein; Jennifer A Sinclair; Priti Bijpuria; Lisa I Jepeal; M Michael Wolfe
Journal:  Regul Pept       Date:  2010-04-28

Review 2.  The role of gut hormones in glucose homeostasis.

Authors:  Daniel J Drucker
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

Review 4.  Consequences of splice variation on Secretin family G protein-coupled receptor function.

Authors:  Sebastian G B Furness; Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.

Authors:  V A Gault; F P M O'Harte; P Harriott; M H Mooney; B D Green; P R Flatt
Journal:  Diabetologia       Date:  2003-02-12       Impact factor: 10.122

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 7.  Gut peptides and type 2 diabetes mellitus treatment.

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 4.810

8.  GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage.

Authors:  Lisa I Jepeal; Michael O Boylan; M Michael Wolfe
Journal:  Mol Cell Endocrinol       Date:  2008-02-08       Impact factor: 4.102

9.  Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes.

Authors:  Dhananjay Gupta; Mina Peshavaria; Navjot Monga; Thomas L Jetton; Jack L Leahy
Journal:  Diabetes       Date:  2010-03-23       Impact factor: 9.461

10.  Molecular mechanisms underlying nutrient detection by incretin-secreting cells.

Authors:  Frank Reimann
Journal:  Int Dairy J       Date:  2010-04       Impact factor: 3.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.